Correspondence 0001213900-23-094438 from TFF Pharmaceuticals, Inc. (TFFP) (CIK 0001733413)
TFF Pharmaceuticals, Inc. (TFFP) (CIK 0001733413)
Date: Dec. 8, 2023 · CIK: 0001733413 · Accession: 0001213900-23-094438
AI Filing Summary & Sentiment
File numbers found in text: 333-275692
Letter
TFF Pharmaceuticals, Inc.
1751 River Run, Suite 400
Fort Worth, Texas 76107
December 8, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn:
Tim Buchmiller
Re:
TFF Pharmaceuticals, Inc.
Registration Statement on Form S-3
File No. 333-275692
Acceleration Request
Requested Date:
Tuesday, December 12, 2023
Requested Time:
4:30 p.m., Eastern Standard Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant, TFF Pharmaceuticals, Inc. (the “Registrant”), hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the Registration Statement on Form S-3 (File No. 333-275692) (the “Registration Statement”) to become effective on December 12, 2023, at 4:30 p.m., Eastern Standard Time, or as soon as practicable thereafter, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission (the “Staff”). The Registrant hereby authorizes Daniel Donahue of Greenberg Traurig, LLP, counsel to the Registrant, to make such request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Daniel Donahue of Greenberg Traurig, LLP, counsel to the Registrant, at (949) 732-6557.
In connection with this request, the Registrant acknowledges that:
•
should the Commission or the Staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
•
the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
•
the Registrant may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
TFF Pharmaceuticals, Inc.
Show Raw Text
CORRESP
1
filename1.htm
TFF Pharmaceuticals, Inc.
1751 River Run, Suite 400
Fort Worth, Texas 76107
December 8, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn:
Tim Buchmiller
Re:
TFF Pharmaceuticals, Inc.
Registration Statement on Form S-3
File No. 333-275692
Acceleration Request
Requested Date:
Tuesday, December 12, 2023
Requested Time:
4:30 p.m., Eastern Standard Time
Ladies and Gentlemen:
In accordance with Rule
461 under the Securities Act of 1933, as amended, the undersigned registrant, TFF Pharmaceuticals, Inc. (the “Registrant”),
hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause
the Registration Statement on Form S-3 (File No. 333-275692) (the “Registration Statement”) to become effective
on December 12, 2023, at 4:30 p.m., Eastern Standard Time, or as soon as practicable thereafter, or at such later time as the Registrant
may orally request via telephone call to the staff of the Commission (the “Staff”). The Registrant hereby authorizes
Daniel Donahue of Greenberg Traurig, LLP, counsel to the Registrant, to make such request on its behalf.
Once the Registration
Statement has been declared effective, please orally confirm that event with Daniel Donahue of Greenberg Traurig, LLP, counsel to the
Registrant, at (949) 732-6557.
In connection with this
request, the Registrant acknowledges that:
•
should the Commission or the Staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
•
the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
•
the Registrant may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
TFF Pharmaceuticals, Inc.
By:
/s/ Harlan Weisman
Harlan Weisman, M.D.,
Chief Executive Officer
cc:
Daniel Donahue, Greenberg Traurig, LLP